Product Description: McMMAF (Maleimidocaproyl monomethylauristatin F) is a maleimido-caproyl linker, made by coupling the powerful microtubule inhibitor Monomethyl auristatin F (MMAF) with the protecting group maleimidocaproyl. McMMAF serves as an active molecule linker for ADC. McMMAF is non-cleavable and must be internalized and degraded within the cell to release cysteine-McMMAF as the active molecule. McMMAF can be conjugated with anti-BCMA antibodies to form J6M0-mcMMAF, promoting apoptosis and inhibiting tumor growth[1][2][3][4].
Applications: Cancer-programmed cell death
Formula: C49H76N6O11
References: [1]Polson AG, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res. 2009 Mar 15;69(6):2358-2364./[2]Jianmin Fang, et al. Anti-her2 antibody and conjugate thereof. US 20160304621 A1./[3]Yu-Tzu Tai, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014 May 15;123(20):3128-38. /[4]Katja Weisel, et al. Dreamm-3: A Phase 3, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin (GSK2857916) Monotherapy Compared with Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 13 November 2019, Page 1900.
CAS Number: 863971-19-1
Molecular Weight: 925.16
Compound Purity: 99.96
Research Area: Cancer
Solubility: DMSO : ≥ 100 mg/mL
Target: Apoptosis;Drug-Linker Conjugates for ADC
Deutsch
English
